Aims: Due to frequent relapses after initial ablation, there is need to develop accurate and practical preoperative means to predict atrial fibrillation (AF) ablation outcome.
BACKGROUND
Atrial fibrillation (AF) is a deleterious arrhythmia with multiple aetiological factors. It requires complex and individualized treatment. During the last decade, radiofrequency catheter ablation (RFA) has become an important treatment option in patients with drug-refractory AF [1] [2] [3] [4] [5] [6] . It is well established that the efficacy of RFA is better among patients with paroxysmal compared to those with persistent or long-standing persistent AF [7, 8] . Traditionally, the decision about ablation has been made on the basis of procedural risk, patient's age, cardiac comorbidities, left atrial (LA) size and the type of AF (e.g., paroxysmal, persistent, long-standing persistent) [1] . However, relapses after the initial ablation are common also in patients with no comorbidities, and multiple procedures are required to achieve clinical efficacy in about 20-40% of the patients with lone paroxysmal AF [8] [9] [10] [11] .
Hence, there is urgent need to identify patients with more complex arrhythmic substrate in order to find those who are most likely to benefit from ablation therapy and to guide ablation strategy. Mahnkopf, et al. recently demonstrated that the extend of fibrosis in the atria detected by a specific magnetic resonance imaging (MRI) technique correlated with the success of AF ablation [12] . As a non-invasive and more readily available diagnostic tool, echocardiography might provide a more practical preoperative means to predict AF ablation outcome. In this study, we evaluated the prognostic value of diastolic echocardiographic parameters in predicting the outcome of RFA of AF.
METHODS

Study Population
A total of 49 patients with symptomatic and drug refractory AF, who underwent wide circumferential pulmonary vein isolation (PVI) procedure, were included in this prospective study. AF was paroxysmal in 25, persistent in 17 and long-standing persistent in 7 patients, respectively. Patients with previous left-sided catheter ablation, open heart surgery, severe structural heart disease (e.g., congenital heart disease, prior myocardial infarction, chronic heart failure, severe valvular heart disease), significant extra-cardiac comorbidities, enlarged left atria (>50 mm) or intracardiac thrombi in transesophageal echocardiography were excluded. The study was approved by the local ethical committee and a written consent for participation was obtained from all patients. 
Echocardiography
Medication
Oral anticoagulation with stable international normalized ratio of 2.0 or higher was ensured at least three weeks before the ablation. After transseptal puncture, intravenous heparin was administered according to our institutional standards without monitoring the activated clotting time [13] . Antiarrhythmic drugs (AAD) were not discontinued at the time of the echocardiographic examination and the ablation procedure. After the ablation, antiarrhythmic medication was allowed upon physician´s discretion during the initial three months blanking period. Thereafter, supplementary AAD therapy was discouraged. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers were used commonly in hypertensive patients.
Ablation Procedure
A three-dimensional electroanatomical map of the left atrium and the PVs was constructed using a nonfluoroscopic navigation system (Carto , Biosense Webster, Diamond Bar, CA, USA) as described previously [13] . The ostia of the PVs were identified by fluoroscopic visualisation with the help of PV angiography or previously acquired computed tomography or MRI image. PVs were isolated pairwisely by creating a wide circumferential line around the right-and left-sided veins using an open-irrigated ablation catheter (Navistar Thermocool, Biosense Webster). Electrical isolation of the PVs was confirmed by careful remap of the lines and PV ostia or by using a circumferential diagnostic catheter.
Follow Up
Clinical controls including symptom enquiry, evaluation of medications and 24 hour Holter monitoring were performed at three, six and twelve months. Patients were also informed to contact the hospital in case of arrhythmia symptoms for Holter monitoring and clinical evaluation. Early AF relapses during the three-month blanking period were treated by electrical cardioversion and antiarrhythmic drug therapy if necessary. In patients free of AF, AADs were discontinued three months after the procedure. Treatment success was defined as freedom of symptoms and documented AF or atrial tachyarrhythmia without concomitant AAD therapy after the blanking period.
Statistical Analysis
IBM SPSS Statistics 20.0 (IBM Corp., Armonk, NY, USA) was used for statistical analysis. Nominal variables are expressed as numbers or percentages and compared by Fisher's exact test or Chi-square test when appropriate. Ordinal variables are presented as mean ± SD and compared with Wilcoxon Rank sum test. Continuous variables are expressed as mean ± SD and compared with independent variables t test. Variables with a P value of <0.1in univariate analysis were further analysed in multivariate model (logistic regression). All tests were two-sided and a P value of <0.05 was considered statistically significant.
RESULTS
At one year after a single AF ablation procedure 18 out of 49 patients (37%) were free of AF without AADs (group 1), whereas 31 patients (63%) had recurrent symptoms, documented AF relapse or need for AADs after the three month blanking period (group 2). There were no procedurerelated complications. The baseline characteristics of the groups were similar in age (52 ± 8 vs 54 ± 9, P=0.47), comorbidities, previous antiarrhythmic medication (1.5 ± 0.8 vs 1.6 ± 1.1, P = 0.82) and antihypertensive drugs (1.1 ± 0.8 vs 1.1 ± 0.7, P = 0.93). History of cardioversion (CV) was less common in Group 1 (39% vs 73%, P = 0.032) and all seven female patients had AF recurrence ( Table 1 ). The majority of the patients had no underlying diseases (67%). Hypertension was present in 10 patients (20%), coronary artery disease in 3 patients (6%) and lung disease in 3 patients (6%). About half of the patients in both groups had paroxysmal AF (56% vs 48%, P=0.63).
Echocardiography
The results of the echocardiographic measurements are shown in Table 2 . The ratio of early diastolic mitral flow velocity and mitral annular early diastolic velocity (E/e' ratio) was significantly lower in group 1 than in group 2 (6.9 ± 1.4 vs 8.3 ± 2.2, P = 0.034). Left ventricular end systolic volumes were higher in group 1 (49 ± 21 ml vs 38 ± 14 ml, P = 0.048). There was no difference between the groups in LA diameter, LVEF, LV dimensions, LV diastolic volume or mass index, transmitral flow propagation velocities and PV flow indexes.
Multivariate analysis was performed for variables with a P value of < 0.1 (i.e., female gender, CV history, LV end diastolic and systolic volumes, E wave deceleration time and E/e'). In the multivariate model, the E/e' ratio was the most powerful predictor of AF symptom recurrence (OR 1.911; 95% CI 1.046-3.493, P = 0.035) ( Table 3 ). The area under the receiver operating characteristic (ROC) curve was 0.68 (95% CI 0.51-0.84) indicating that the E/e´ratio might predict the outcome of AF ablation, but its accuracy in this relative small population was not good. 
DISCUSSION
In our study, the left ventricular filling pressure measured by the E/e' ratio was an independent and most powerful predictor for AF reoccurrence following single ablation procedure at one year. In addition, transmitral E wave deceleration time was longer in patients with AF relapse, but the traditional risk factors, such as LA size, had no predictive value. However, patients with large LA diameter (> 50 mm) and chronic heart failure were excluded.
In addition to the classical risk factors for AF relapse, other underlying conditions [14, 15] , imaging findings [12, [16] [17] [18] , biomarkers [19, 20] and genetic factors [21] have been noted to predict AF reoccurrence after catheter ablation. Still, the question remains, how we can better identify patients with increased risk for AF relapses. The level of atrial fibrosis has been shown to correlate with AF ablation outcome. Detection of the extent of fibrosis in the atria is possible with a specific delayed enhancement MRI technique [12] . As a non-invasive and more readily available diagnostic tool, echocardiography might provide a more practical preoperative means to predict AF ablation outcome.
In this study, the E/e' ratio was an independent predictor for long-term success of AF ablation. Unlike many other diastolic measurements, which are affected by AF, the E/e' ratio can be measured also during AF [22] . In keeping with our data, results of some previous studies indicate that diastolic dysfunction or heart failure predicts AF recurrence after ablation [23] [24] [25] [26] . It has been shown that LV diastolic dysfunction may promote AF [27] . On the other hand, it is known that the atria are more susceptible to subtle diastolic changes than the ventricles [28] . Nagueh, et al. [29] showed that the E/e' ratio was linearly correlated with LA pressure. In a recent study, invasively measured LA pressure was significantly higher in patients with persistent vs paroxysmal AF [30] . It remains unclear whether the elevation of the E/e' ratio is due to diastolic dysfunction caused by subclinical underlying conditions, genetic factors or higher preoperative AF burden in patients with no response to AF ablation. In keeping with the last hypothesis, we have shown earlier that patients with frequent episodes of symptomatic AF had reduced systolic PV flow during normal sinus rhythm compared to those with few or no episodes of paroxysmal AF [31] . It would be interesting to evaluate whether there is a correlation between the E/e ´ratio and the extent of fibrosis detected by late gadolinium enhancement MRI.
STUDY LIMITATIONS
The study population was rather small and did not allow separate comparison of patients with paroxysmal vs persistent or long-standing persistent AF. Moreover, patients had minor comorbidity. Therefore, one needs to be cautious when extrapolating these results to other patient populations. Nevertheless, our data indicate that in selected cases, simple preoperative echocardiographic measurements may be valuable in tailoring the treatment of the patients. Furthermore, because control electrophysiological study was not performed, the mechanisms behind the AF relapses could not be specified. It is possible that the patients with elevated E/e´ratio have higher risk for PV reconnection or that they require more extensive substrate modification like those with long-standing persistent AF. Finally, despite the apparent clinical benefit, it should be noted that asymptomatic AF episodes may have been under-detected and true AF burden could not be estimated since no continuous ECG monitoring with implantable device was used.
CONCLUSIONS
Our data indicate that E/e' ratio is a powerful predictor of AF reoccurrence after PVI. As a non-invasive, readily available and inexpensive measurement, E/e´ratio is a practical tool to recognize the patients in risk for treatment failure and to refine treatment strategy. Further studies are needed to evaluate its relation to atrial fibrosis and AF burden and to define its role in guiding the treatment strategy.
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